Health care utilization and mortality among elderly patients with myelodysplastic syndromes.

K. J. Lindquist, M. D. Danese, Joseph R Mikhael, K. B. Knopf, R. I. Griffiths

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Mortality in patients with myelodysplastic syndromes (MDS) is high, and patients are likely to require hospitalizations, emergency department (ED) visits, and transfusions. The relationships between these events and the MDS complications of anemia, neutropenia, and thrombocytopenia are not well understood. A total of 1864 patients registered in the United States' Surveillance Epidemiology and End Results (SEER) program and aged ≥ 66 years old when diagnosed with MDS in 2001 or 2002 were included. Medicare claims were used to identify MDS complications and utilization (hospitalizations, ED visits, and transfusions) until death or the end of 2005. Mortality was based on SEER data. Kaplan-Meier incidence rates were estimated and multivariable Cox models were used to study the association between complications and outcomes. The 3-year incidence of anemia, neutropenia, and thrombocytopenia was 81%, 25%, and 41%, and the incidence of hospitalization, ED visit, and transfusion was 62%, 42%, and 45%, respectively. Median survival time was 22 months. Cytopenia complications were significantly associated with each of these outcomes. All types of cytopenia are common among patients with MDS and are risk factors for high rates of health care utilization and mortality. Management of the complications of MDS may improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)1181-1188
Number of pages8
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume22
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Patient Acceptance of Health Care
Myelodysplastic Syndromes
Mortality
Hospital Emergency Service
Hospitalization
Neutropenia
Thrombocytopenia
Anemia
Incidence
SEER Program
Medicare
Proportional Hazards Models
Epidemiology
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Health care utilization and mortality among elderly patients with myelodysplastic syndromes. / Lindquist, K. J.; Danese, M. D.; Mikhael, Joseph R; Knopf, K. B.; Griffiths, R. I.

In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Vol. 22, No. 5, 05.2011, p. 1181-1188.

Research output: Contribution to journalArticle

Lindquist, K. J. ; Danese, M. D. ; Mikhael, Joseph R ; Knopf, K. B. ; Griffiths, R. I. / Health care utilization and mortality among elderly patients with myelodysplastic syndromes. In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011 ; Vol. 22, No. 5. pp. 1181-1188.
@article{c6d9add0111a4c829824946238328175,
title = "Health care utilization and mortality among elderly patients with myelodysplastic syndromes.",
abstract = "Mortality in patients with myelodysplastic syndromes (MDS) is high, and patients are likely to require hospitalizations, emergency department (ED) visits, and transfusions. The relationships between these events and the MDS complications of anemia, neutropenia, and thrombocytopenia are not well understood. A total of 1864 patients registered in the United States' Surveillance Epidemiology and End Results (SEER) program and aged ≥ 66 years old when diagnosed with MDS in 2001 or 2002 were included. Medicare claims were used to identify MDS complications and utilization (hospitalizations, ED visits, and transfusions) until death or the end of 2005. Mortality was based on SEER data. Kaplan-Meier incidence rates were estimated and multivariable Cox models were used to study the association between complications and outcomes. The 3-year incidence of anemia, neutropenia, and thrombocytopenia was 81{\%}, 25{\%}, and 41{\%}, and the incidence of hospitalization, ED visit, and transfusion was 62{\%}, 42{\%}, and 45{\%}, respectively. Median survival time was 22 months. Cytopenia complications were significantly associated with each of these outcomes. All types of cytopenia are common among patients with MDS and are risk factors for high rates of health care utilization and mortality. Management of the complications of MDS may improve patient outcomes.",
author = "Lindquist, {K. J.} and Danese, {M. D.} and Mikhael, {Joseph R} and Knopf, {K. B.} and Griffiths, {R. I.}",
year = "2011",
month = "5",
doi = "10.1093/annonc/mdq552",
language = "English (US)",
volume = "22",
pages = "1181--1188",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Health care utilization and mortality among elderly patients with myelodysplastic syndromes.

AU - Lindquist, K. J.

AU - Danese, M. D.

AU - Mikhael, Joseph R

AU - Knopf, K. B.

AU - Griffiths, R. I.

PY - 2011/5

Y1 - 2011/5

N2 - Mortality in patients with myelodysplastic syndromes (MDS) is high, and patients are likely to require hospitalizations, emergency department (ED) visits, and transfusions. The relationships between these events and the MDS complications of anemia, neutropenia, and thrombocytopenia are not well understood. A total of 1864 patients registered in the United States' Surveillance Epidemiology and End Results (SEER) program and aged ≥ 66 years old when diagnosed with MDS in 2001 or 2002 were included. Medicare claims were used to identify MDS complications and utilization (hospitalizations, ED visits, and transfusions) until death or the end of 2005. Mortality was based on SEER data. Kaplan-Meier incidence rates were estimated and multivariable Cox models were used to study the association between complications and outcomes. The 3-year incidence of anemia, neutropenia, and thrombocytopenia was 81%, 25%, and 41%, and the incidence of hospitalization, ED visit, and transfusion was 62%, 42%, and 45%, respectively. Median survival time was 22 months. Cytopenia complications were significantly associated with each of these outcomes. All types of cytopenia are common among patients with MDS and are risk factors for high rates of health care utilization and mortality. Management of the complications of MDS may improve patient outcomes.

AB - Mortality in patients with myelodysplastic syndromes (MDS) is high, and patients are likely to require hospitalizations, emergency department (ED) visits, and transfusions. The relationships between these events and the MDS complications of anemia, neutropenia, and thrombocytopenia are not well understood. A total of 1864 patients registered in the United States' Surveillance Epidemiology and End Results (SEER) program and aged ≥ 66 years old when diagnosed with MDS in 2001 or 2002 were included. Medicare claims were used to identify MDS complications and utilization (hospitalizations, ED visits, and transfusions) until death or the end of 2005. Mortality was based on SEER data. Kaplan-Meier incidence rates were estimated and multivariable Cox models were used to study the association between complications and outcomes. The 3-year incidence of anemia, neutropenia, and thrombocytopenia was 81%, 25%, and 41%, and the incidence of hospitalization, ED visit, and transfusion was 62%, 42%, and 45%, respectively. Median survival time was 22 months. Cytopenia complications were significantly associated with each of these outcomes. All types of cytopenia are common among patients with MDS and are risk factors for high rates of health care utilization and mortality. Management of the complications of MDS may improve patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=79961232055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961232055&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq552

DO - 10.1093/annonc/mdq552

M3 - Article

C2 - 21041376

AN - SCOPUS:79961232055

VL - 22

SP - 1181

EP - 1188

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -